Welcome
Support Centre
30 October 2014 
Current Controlled Trials - Clinical Trials
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Introduction
English introduction Introduction en franais Deutsche einleitung
Introduccin espaola Introduzione in italiano
 
Find trials
active registers
mental health register
archived registers
all registers
tips on searching
 
 
Information
about mRCT
mRCT FAQs

DISCLAIMER
The site should not be used to diagnose or treat a health problem. Please consult your doctor.
Terms & conditions

DUPLICATION
Your search result may contain a number of different records for the same trial. This occurs when the same trial is listed in more than one register.

[ Print-friendly version ]
Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia
Link to the ClinicalTrials.gov recordInformation obtained from ClinicalTrials.gov on February 23, 2012
Title of trial/grant titleDasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia
Current status of trialCompleted
Sponsors and collaboratorsBristol-Myers Squibb
Information provided byBristol-Myers Squibb
ClinicalTrials.gov identifierNCT00103844
PurposeThe primary purpose of this study is to estimate the major cytogenetic response rates of
BMS-354825 and imatinib (800 mg/d) in subjects with chronic phase, Philadelphia chromosome
positive, chronic myeloid leukemia (PH+ CML) with disease resistant to imatinib at a dose of
400-600 mg/d.
Condition(s)Chronic Myeloid Leukemia
Philadelphia-Positive Myeloid Leukemia
Intervention(s)Drug: Dasatinib
Drug: Imatinib
PhasePhase II
Study type and designAllocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
Official titleA Randomized Multi-Center Open Label Study of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjects With Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Disease That is Resistant to Imatinib at a Dose at 400 - 600 mg/d
Primary outcomeNumber of Participants With Major Cytogenetic Response (MCyR) at Week 12 Week 12 No Cytogenetic response was based on the prevalence of Philadelphia chromosome positive (Ph+) metaphases among cells in metaphase on a bone marrow sample (aspirate/biopsy). MCyR was defined as Complete CyR (CCyR; 0% Ph+ cells in metaphase in bone marrow) or Partial CyR (PCyR; >0% to 35% Ph+ cells in metaphase in bone marrow).
Secondary outcomeMCyR at Any Time Prior to Crossover Baseline (within 4 weeks of Day 1), every 12 weeks until crossover or off-study timepoints. Restricted to precrossover measurements. No Cytogenetic response was based on the prevalence of Ph+ metaphases among cells in metaphase on a bone marrow sample (aspirate/biopsy). MCyR was defined as CCyR (0% Ph+ cells in metaphase in bone marrow) or PCyR (>0% to 35% Ph+ cells in metaphase in bone marrow).
Duration of MCyR at 12 Months and 18 Months 12 months, 18 months No Percentage of participants who achieved MCyR and did not progress at 12 and 18 months.
Duration of MCyR at 24 Months 24 Months No Percentage of participants who achieved MCyR and did not progress at 24 months.
Time to MCyR Prior to Crossover Baseline (within 4 weeks of Day 1), every 12 weeks, at crossover or off-study timepoints; restricted to precrossover measurements. No Median time from first dosing date to date of MCyR
Complete Hematologic Response (CHR) at Any Time Prior to Crossover Baseline (within 4 weeks of Day 1), weekly until Week 12 and then every 12 weeks until crossover or off-study; restricted to precrossover measurements. No Participants achieving CHR prior to crossover. CHR=all of the following criteria: white blood cell count ⿤ institutional upper limit of normal; platelets < 450,000/mm³; no blasts or promyelocytes in peripheral blood; < 5% myelocytes plus metamyelocytes in peripheral blood; peripheral blood basophils ⿤ 20%; no extramedullary involvement. Confirmed CHR is defined as CHR maintained at least 4 weeks after first documented at ⿥ Day 14. Failure to maintain criteria of CHR was defined by 2 or more consecutive records of non-response.
Duration of Complete Hematologic Response (CHR) 12 months, 24 months No Percentage of participants who achieved CHR and did not progress at specified time points. CHR=all of the following criteria: white blood cell count ⿤ institutional upper limit of normal; platelets < 450,000/mm³; no blasts or promyelocytes in peripheral blood; < 5% myelocytes plus metamyelocytes in peripheral blood; peripheral blood basophils ⿤ 20%; no extramedullary involvement. Confirmed CHR is defined as CHR maintained at least 4 weeks after first documented at ⿥ Day 14. Failure to maintain criteria of CHR was defined by 2 or more consecutive records of non-response.
Time to CHR Prior to Crossover Baseline (within 4 weeks of Day 1), weekly until Week 12, then every 12 weeks until crossover or off-study; restricted to precrossover measurements. No Median time from first dosing date to date of CHR. CHR=all of the following criteria: white blood cell count ⿤ institutional upper limit of normal; platelets < 450,000/mm³; no blasts or promyelocytes in peripheral blood; < 5% myelocytes plus metamyelocytes in peripheral blood; peripheral blood basophils ⿤ 20%; no extramedullary involvement. Confirmed CHR is defined as CHR maintained at least 4 weeks after first documented at ⿥ Day 14. Failure to maintain criteria of CHR was defined by 2 or more consecutive records of non-response.
Major Molecular Response (MMR) Pretreatment, then after every 4 weeks for 12 weeks, then after every 12 week period out to 2 years; restricted to precrossover measurements. No Number of participants Achieving MMR. MMR is defined as ⿤3 log reduction (ie, international ratio ⿤0.1), in BCR-ABL levels from the standardized baseline value of BCR-ABL: Control Gene ratio. The international ratio is obtained by multiplying BCR-ABL: Control gene ratio by the lab-specific conversion factor.
CHR After Crossover Weekly for 12 weeks, then after every 12 week period out to 2 years; restricted to postcrossover measurements. No Participants achieving CHR after crossover. CHR=all of the following criteria: white blood cell count ⿤ institutional upper limit of normal; platelets < 450,000/mm³; no blasts or promyelocytes in peripheral blood; < 5% myelocytes plus metamyelocytes in peripheral blood; peripheral blood basophils ⿤ 20%; no extramedullary involvement. Confirmed CHR is defined as CHR maintained at least 4 weeks after first documented at ⿥ Day 14. Failure to maintain criteria of CHR was defined by 2 or more consecutive records of non-response.
Cytogenetic Response After Crossover every 12 week period out to 2 years and off-study timepoints; restricted to postcrossover measurements No Cytogenetic response was based on the prevalence of Ph+ metaphases among cells in metaphase on a bone marrow sample (aspirate/biopsy). MCyR was defined as Complete CyR (0% Ph+ cells in metaphase in bone marrow) or Partial CyR (>0% to 35% Ph+ cells in metaphase in bone marrow).
Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths and Hematologic Toxicities Prior to Crossover Continuously from baseline through 2 years Yes AE=any new untoward medical occurrence or worsening of a pre-existing medical condition regardless of causal relationship with treatment. SAE=any untoward medical occurrence at any dose that: results in death; is life-threatening; requires or prolongs inpatient hospitalization; results in persistent or significant disability; is cancer; is congenital anomaly/birth defect; results in drug dependency/abuse; is an important medical event. Graded by National Cancer Institute Common Terminology Criteria for Adverse Events v3.0. (1=Mild, 2=Moderate, 3=Severe, 4=Life-threatening/disabling, 5=Death)
Health-Related Quality of Life Prior to Crossover Every 4 weeks for the first 24 weeks, then every 12 weeks for the remainder of treatment. Last questionnaire was to be completed at first follow-up visit after off-study date. No Health-related quality of life as measured by Functional Assessment of Cancer Therapy-General (FACT-G). FACT-G=27 questions in 4 domains: physical, social/family, emotional, & functional well-being (PWB, SWB, EWB, FWB). Higher scores=better health-related quality of life. Total Score change of 7 or more=minimal clinical important change; PWB, EWB, & FWB score change of 3 or more, & SWB score change of 2 or more=minimal clinical important change.
Blood Sample Collection for Pharmacokinetic (PK) Analysis of Dasatinib Day 8: pretreatment trough sample, a sample between 30 minutes and 3 hours following treatment, a sample between 5 and 8 hours following treatment, and a sample at 12 hours, prior to the next dose. No Number of participants from which blood samples were collected for population PK studies.
Study startFebruary 2005
Minimum age18 Years
Maximum ageN/A
GenderBoth
Eligibility criteriaInclusion Criteria:

- Men and women, 18 years of age or older.

- Subjects with Chronic Phase Ph+ CML.

- Subjects have not been treated with imatinib at a dose >600 mg/day.

- Subjects developed resistance to disease while receiving an imatinib dose 400-600
mg/day.

- Able to tolerate imatinib at the highest dose the subject had received in the past.

- Demonstrate adequate renal and hepatic function.

- Women of childbearing potential must have a negative serum or urine pregnancy test,
must be using an adequate method of contraception.

Exclusion Criteria:

- Women who are unwilling or unable to use an acceptable method to avoid pregnancy for
the entire study period for a least 1 month before and at least 3 months after the
completion of the study.

- Women using a prohibited contraceptive method.

- Women who are pregnant or breastfeeding.

- Men whose sexual partners are women who are of childbearing potential, and who are
unwilling or unable to use an acceptable method to avoid pregnancy of his partner for
the entire study period as outlined above.

- Prior treatment with imatinib at a dose >600 mg/day.

- Subjects who have previously identified specific BCR-ABL mutations.

- Previous diagnosis of accelerated phase or blast crisis CML.

- Intolerance to imatinib at any dose.

- Subjects who are eligible and willing to undergo transplantation during the screening
period.

- Serious uncontrolled medical disorder or active infection.

- Uncontrolled or significant cardiovascular disease.

- Uncontrolled hypertension.

- Dementia or altered mental status.

- Evidence of organ dysfunction.

- Use of imatinib within 7 days.

- Use of interferon or cytarabine within 14 days.

- Use of a targeted small molecule anticancer agent within 14 days.

- Subjects taking certain medications that are accepted to have a risk of causing
Torsades de Pointes.

- Subjects taking medications that irreversibly inhibit platelet function or
anticoagulants.

- Prior therapy with BMS-354825.
Study chairs or principal investigatorsBristol-Myers Squibb, Study Director, Bristol-Myers Squibb
LocationsAlabama, United States

Local Institution
Birmingham
Alabama

California, United States

Local Institution
Anaheim
California

California, United States

Local Institution
Bakersfield
California

California, United States

Local Institution
Fullerton
California

California, United States

Local Institution
Loma Linda
California

California, United States

Local Institution
Los Angeles
California

California, United States

Local Institution
Monterey Park
California

California, United States

Local Institution
San Diego
California

California, United States

Local Institution
Santa Barbara
California

California, United States

Local Institution
Santa Maria
California

California, United States

Local Institution
Stanford
California

California, United States

Local Institution
Vallejo
California

Colorado, United States

Local Institution
Aurora
Colorado

Connecticut, United States

Local Institution
Hartford
Connecticut

District of Columbia, United States

Local Institution
Washington
District of Columbia

Florida, United States

Local Institution
Jacksonville
Florida

Florida, United States

Local Institution
Tampa
Florida

Georgia, United States

Local Institution
Athens
Georgia

Georgia, United States

Local Institution
Atlanta
Georgia

Georgia, United States

Local Institution
Lawrenceville
Georgia

Georgia, United States

Local Institution
Tucker
Georgia

Illinois, United States

Local Institution
Chicago
Illinois

Illinois, United States

Local Institution
Peoria
Illinois

Indiana, United States

Local Institution
Indianapolis
Indiana

Kansas, United States

Local Institution
Kansas City
Kansas

Kentucky, United States

Local Institution
Lexington
Kentucky

Massachusetts, United States

Local Institution
Boston
Massachusetts

Minnesota, United States

Local Institution
Minneapolis
Minnesota

Minnesota, United States

Local Institution
Rochester
Minnesota

Missouri, United States

Local Institution
Columbia
Missouri

Missouri, United States

Local Institution
Kansas City
Missouri

Missouri, United States

Local Institution
St. Louis
Missouri

Nebraska, United States

Local Institution
Omaha
Nebraska

New Jersey, United States

Local Institution
Hackensack
New Jersey

New Jersey, United States

Local Institution
Morristown
New Jersey

New Jersey, United States

Local Institution
New Brunswick
New Jersey

North Carolina, United States

Local Institution
Cary
North Carolina

North Carolina, United States

Local Institution
Chapel Hill
North Carolina

Oklahoma, United States

Local Institution
Oklahoma City
Oklahoma

Oklahoma, United States

Local Institution
Tulsa
Oklahoma

Oregon, United States

Local Institution
Portland
Oregon

Pennsylvania, United States

Local Institution
Pittsburgh
Pennsylvania

South Carolina, United States

Local Institution
Greenville
South Carolina

Tennessee, United States

Local Institution
Nashville
Tennessee

Texas, United States

Local Institution
Dallas
Texas

Texas, United States

Local Institution
Fort Worth
Texas

Texas, United States

Local Institution
Houston
Texas

Texas, United States

Local Institution
San Antonio
Texas

Texas, United States

Local Institution
Tyler
Texas

Virginia, United States

Local Institution
Norfolk
Virginia

Washington, United States

Local Institution
Seattle
Washington

Washington, United States

Local Institution
Spokane
Washington

Washington, United States

Local Institution
Vancouver
Washington

Argentina

Local Institution
Buenos Aires

Argentina

Local Institution
Cordoba

New South Wales, Australia

Local Institution
Camperdown
New South Wales

New South Wales, Australia

Local Institution
St. Leonards
New South Wales

Queensland, Australia

Local Institution
South Brisbane
Queensland

South Australia, Australia

Local Institution
Adelaide
South Australia

Western Australia, Australia

Local Institution
Perth
Western Australia

Austria

Local Institution
Wein

Belgium

Local Institution
B-Leuven

Belgium

Local Institution
Brugge

Belgium

Local Institution
Bruxelles

Belgium

Local Institution
Charleroi

Belgium

Local Institution
Edegem

Belgium

Local Institution
Yvoir

Parana, Brazil

Local Institution
Curitiba
Parana

Brazil

Local Institution
Rio De Janeiro

Brazil

Local Institution
Sao Paulo

Alberta, Canada

Local Institution
Edmonton
Alberta

British Columbia, Canada

Local Institution
Vancouver
British Columbia

Ontario, Canada

Local Institution
Toronto
Ontario

Quebec, Canada

Local Institution
Montreal
Quebec

China

Local Institution
Beijing

China

Local Institution
Shanghai

Denmark

Local Institution
Aarhus

Estonia

Local Institution
Tallin

Finland

Local Institution
Helsinki

France

Local Institution
Lille

France

Local Institution
Lyon Cedex 03

France

Local Institution
Nantes

France

Local Institution
Paris

France

Local Institution
Pessac

France

Local Institution
Poitiers

France

Local Institution
Strasbourg Cedex

Germany

Local Institution
Dresden

Germany

Local Institution
Groenkloof

Germany

Local Institution
Hamburg

Germany

Local Institution
Leipzig

Germany

Local Institution
Mainz

Germany

Local Institution
Mannheim

Hungary

Local Institution
Budapest

Ireland

Local Institution
Dublin

Israel

Local Institution
Ramat-Gan

Italy

Local Institution
Bari

Italy

Local Institution
Bologna

Italy

Local Institution
Milano

Italy

Local Institution
Napoli

Italy

Local Institution
Orbassano

Italy

Local Institution
Roma

Korea, Republic of

Local Institution
Kyunggi-Do

Norway

Local Institution
Trondheim

Peru

Local Institution
Lima

Philippines

Local Institution
Quezon City

Poland

Local Institution
Katowice

Poland

Local Institution
Krakow

Poland

Local Institution
Lublin

Poland

Local Institution
Warsaw

Puerto Rico

Local Institution
San Juan

Russian Federation

Local Institution
Moscow

Russian Federation

Local Institution
St. Petersburg

Singapore

Local Institution
Singapore

Free State, South Africa

Local Institution
Bloemfontein
Free State

Gauteng, South Africa

Local Institution
Parktown
Gauteng

Gauteng, South Africa

Local Institution
Soweto
Gauteng

Spain

Local Institution
Barcelona

Spain

Local Institution
Madrid

Sweden

Local Institution
Gothenburg

Sweden

Local Institution
Lund

Sweden

Local Institution
Stockholm

Sweden

Local Institution
Umea

Sweden

Local Institution
Uppsala

Switzerland

Local Institution
Basel

Switzerland

Local Institution
Bellinzona

Taiwan

Local Institution
Taipei

Taiwan

Local Institution
Taoyuan

Thailand

Local Institution
Bangkok

Central, United Kingdom

Local Institution
Glasglow
Central

Greater London, United Kingdom

Local Institution
London
Greater London

Tyne and Wear, United Kingdom

Local Institution
Newcastle
Tyne and Wear
LinksBMS Clinical Trials Disclosure
For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm
PublicationsKantarjian H, Pasquini R, Lévy V, Jootar S, Holowiecki J, Hamerschlak N, Hughes T, Bleickardt E, Dejardin D, Cortes J, Shah NP. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer. 2009 Sep 15;115(18):4136-47.

Müller MC, Cortes JE, Kim DW, Druker BJ, Erben P, Pasquini R, Branford S, Hughes TP, Radich JP, Ploughman L, Mukhopadhyay J, Hochhaus A. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood. 2009 Dec 3;114(24):4944-53. Epub 2009 Sep 24.
Study ID numbersCA180-017
Last updatedAugust 3, 2010
Record first receivedFebruary 15, 2005
ClinicalTrials.gov identifierNCT00103844
Download dateInformation obtained from ClinicalTrials.gov on February 23, 2012
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2014 Current Controlled Trials Ltd. Part of Springer Science+Business Media. | terms & conditions | privacy statement | cookies